Overview

Study Evaluating ReFacto AF in Severe Hemophilia A

Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
To characterize the safety and efficacy of ReFacto AF in treating acute bleeding episodes during prophylaxis treatment, including neoantigenicity.
Phase:
Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Factor VIII